Esperion Therapeutics Inc. (ESPR) concluded trading on Tuesday at a closing price of $2.72, with 4.48 million shares of worth about $12.18 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 49.45% during that period and on June 18, 2024 the price saw a loss of about -5.23%. Currently the company’s common shares owned by public are about 170.42M shares, out of which, 154.69M shares are available for trading.
Stock saw a price change of -6.21% in past 5 days and over the past one month there was a price change of 15.25%. Year-to-date (YTD), ESPR shares are showing a performance of -9.03% which increased to 91.55% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.70 but also hit the highest price of $3.40 during that period. The average intraday trading volume for Esperion Therapeutics Inc. shares is 8.16 million. The stock is currently trading 8.95% above its 20-day simple moving average (SMA20), while that difference is up 18.41% for SMA50 and it goes to 40.83% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Esperion Therapeutics Inc. (NASDAQ: ESPR) currently have 170.42M outstanding shares and institutions hold larger chunk of about 71.03% of that.
The stock has a current market capitalization of $463.54M and its 3Y-monthly beta is at 1.07. It has posted earnings per share of -$1.01 in the same period. It has Quick Ratio of 1.78. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ESPR, volatility over the week remained 8.10% while standing at 8.51% over the month.
Stock’s fiscal year EPS is expected to rise by 97.29% while it is estimated to increase by 506.94% in next year. EPS is likely to shrink at an annualized rate of 16.90% for next 5-years, compared to annual growth of 23.09% made by the stock over the past 5-years.
On August 01, 2023, Northland Capital Upgrade their recommendations, while on June 15, 2023, BofA Securities Upgrade their ratings for the stock with a price target of $4. Stock get an Under perform rating from Northland Capital on March 16, 2023.
